New River reiterated at buy by Merrill

New River Pharmaceuticals Inc. was reiterated at buy by Merrill Lynch analyst David Munno on new that abstracts for the company's phase 2 and phase 3 studies of NRP104 became available. Data described in the abstracts are consistent with what the company has previously presented. The abstract for the phase 2 data indicate that NRP104 and Adderall XR had comparable, significant improvements in ADHD symptom control versus a placebo while the abstract for phase 3 data indicated that patients receiving NRP104 had significant improvements in ADHD symptoms with all doses compared with a placebo. Shares of the Radford, Va., pharmaceutical company were up 84 cents, or 2.73%, at $31.61 on volume of 281,192 shares versus the three-month running average of 270,744 shares. (Nasdaq: NPPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.